Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Research & Studies
Share your love
Eyes May Offer Early Clues to Alzheimer’s Disease
Researchers at Cedars-Sinai have conducted the most comprehensive analysis of retinal changes in Alzheimer’s disease patients and their correlation with brain and cognitive changes. The findings of this study, which have been published in the journal Acta Neuropathologica, are crucial…
Positive Results for Dry AMD Treatment by LumiThera
LumiThera announced the 24-month data from its LIGHTSITE III multicenter clinical trial. The results showed sustained vision improvement in subjects with dry age-related macular degeneration (AMD) who were treated with the Valeda Light Delivery System. LumiThera conducted LIGHTSITE III, a…
Gene Therapy for Retinitis Pigmentosa Shows Promise
People with retinitis pigmentosa typically experience changes in their vision during childhood or early adulthood. The condition commonly results in a decline in both peripheral and night vision, ultimately leading to blindness in the majority of cases. A team of…
Apellis’ Syfovre for Treatment of GA Approved by FDA
The FDA has approved Apellis Pharmaceuticals’ Syfovre (pegcetacoplan) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). This marks the first time that patients with GA have an FDA-approved treatment option, which is a significant milestone…
Sight Sciences Unveils Ergo-Series for OMNI
Sight Sciences has launched the Ergo-Series of the OMNI Surgical System in the US, which is specifically designed to help surgeons in performing minimally invasive, implant-free glaucoma procedures in adults suffering from primary open-angle glaucoma. The OMNI Surgical System facilitates…
Benefits Of Combination Drops On Glaucoma Management
When patients are diagnosed with glaucoma, one of the most common treatment options is a prescription eye drop medication that lowers eye pressure, which prevents damage to the optic nerve and helps to preserve vision. Several types of drugs lower…
VSY Biotechnology Picks The Stars Of Ophthalmology
With its booth, and scientific and social events, VSY Biotechnology was the center of attention at the 37th Congress of the European Society of Cataract and Refractive Surgeons (ESCRS), the world’s premier ophthalmology event. VSY Biotechnology organized the Stars of…
A Next-Gen Monofocal IOL From Johnson & Johnson Vision
Johnson & Johnson Vision Announces Launch of TECNIS Eyhance™ Toric II IOL with TECNIS Simplicity™ Delivery System, a Next-Generation Monofocal Intraocular Lens for Cataracts Patients with Astigmatism, in Europe TECNIS Eyhance™ Toric II IOL offers all the benefits associated with…
VSY Biotech Signs Agreement With WAKAMOTO Pharma
Leinfelden – Echterdingen, Germany March 19, 2021, VSY Biotechnology GmbH, an innovation-driven company with its progressive R&D activities in ophthalmology, visco supplementation in orthopedy and medical esthetics, announced today an agreement with WAKAMOTO PHARMACEUTICAL CO., LTD. (hereinafter refer to…
Updates On Central Serous Chorioretinopathy
Central serous chorioretinopathy, commonly referred to as CSC, is a condition in which fluid accumulates under the retina, causing a serous (fluid-filled) detachment and vision loss. CSC most often occurs in young and middle-aged adults. For unknown reasons, men develop…